Dynamic Observational Study With PET of 68Ga-HER2-affibody in Anti-HER2 Treatment
Status: RECRUITING
Study type: OBSERVATIONAL
Conditions: Breast Cancer
Interventions: DRUG: Docetaxel combined with Trastuzumab±Pertuzumab|DRUG: T-DM1 or Capecitabine combined with Pyrotinib regimen.
Sponsor: Fudan University